---
title: "TD Cowen maintains Buy rating on Elevance Health, $495 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302885247.md"
description: "TD Cowen maintains a Buy rating on Elevance Health with a $495 price target, implying an 11.2% upside from the Oct 22 close. The firm cites strong earnings growth potential, evidenced by recent EPS beats and raised estimates for 2026-2027. Additionally, Elevance's market position as the largest Blue Cross Blue Shield provider, strategic acquisitions, and expanding pharmacy benefit management presence enhance its competitive edge and revenue diversification."
datetime: "2026-10-23T13:16:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302885247.md)
  - [en](https://longbridge.com/en/news/302885247.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302885247.md)
generator: "portal-rs"
---

# TD Cowen maintains Buy rating on Elevance Health, $495 price target

TD Cowen maintained their Buy rating on Elevance Health's stock with a price target of $495.00.

The price target implies an upside of 11.2% from the Oct 22 close of $445.28.

**Key takeaways from the analyst note**

**Strong Earnings Growth Potential**: Elevance Health's recent earnings report showed a solid EPS beat, leading to an increase in 2026 and 2027 EPS estimates, which reflects the company's ability to generate profitable growth and meet investor expectations.

**Expanding Market Reach and Diversification**: Elevance's unique position as the largest provider of Blue Cross Blue Shield coverage across multiple states, combined with strategic acquisitions and its growing presence in pharmacy benefit management, enhances its competitive edge and diversifies its revenue streams, making it an attractive investment.

Explore more price target data and ratings for Elevance Health on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md)
- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [Elevance Health, Inc. $ELV Stock Position Cut by Vontobel Holding Ltd.](https://longbridge.com/en/news/302257360.md)
- [Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion](https://longbridge.com/en/news/302542349.md)
- [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**